Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Curis, Genentech Begin Phase II Skin Cancer Trial | Contract Pharma

What are you searching for?

Sign in

Curis, Genentech Begin Phase II Skin Cancer Trial

Curis, Inc. and Genentech have initiated a Phase II trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Curis, Inc. and Genentech have initiated a Phase II trial of GDC-0449, an orally-administered small molecule Hedgehog Pathway Inhibitor, as a single-agent therapy for patients with operable basal cell carcinoma (BCC).

The companies continue to work with clinical investigators to evaluate GDC-0449 in other diseases with Hedgehog-pathway mutations such as medulloblastoma, a childhood brain cancer and in BCCs in basal cell nevus (Gorlin) syndrome, a rare genetic disorder in which patients typically develop multiple BCCs over their lifetime.

Genentech/Roche is developing GDC-0449 in advanced BCC, a severe form of the disease that includes cutaneous BCCs that are inoperable and have metastasized to other tissues and organs. Previously reported data from a Phase I trial in patients suffering from advanced BCC showed a 55% response rate in 33 advanced BCC patients. Enrollment in a 100-patient Phase II trial of GDC-0449 in advanced BCC has been completed and data is expected from this study in 1H11 with potential regulatory submissions in 2011.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters